These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36200096)

  • 61. Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial.
    Li Q; Guan X; Chen S; Yi Z; Lan B; Xing P; Fan Y; Wang J; Luo Y; Yuan P; Cai R; Zhang P; Li Q; Zhong D; Zhang Y; Zou J; Zhu X; Ma F; Xu B
    Clin Cancer Res; 2019 Sep; 25(17):5212-5220. PubMed ID: 31138588
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Cardiotoxicity monitoring of pyrotinib in combination with nab-paclitaxel, doxorubicin, and cyclophosphamide in HER2-positive breast cancer: a single-armed clinical trial.
    Wang W; Wang L; Chang JY; Hu F; Yan JY; Zhang J; Liang YP; Zhang HW; Wu HP; Cai HF
    Gland Surg; 2022 Apr; 11(4):742-750. PubMed ID: 35531104
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Incidence and management of pyrotinib-associated diarrhea in HER2-positive advanced breast cancer patients.
    Fang C; Wen J; Kang M; Zhang Y; Chen Q; Ren L
    Ann Palliat Med; 2022 Jan; 11(1):210-216. PubMed ID: 35144412
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer: A Multicenter, Prospective, Real-World Study.
    Zhang L; Wu X; Zhou J; Zhu M; Yu H; Zhang Y; Zhao Y; Han Z; Guo Y; Guan X; Wang X; Xu H; Sun L; Zhang J; Zhuang M; Xie L; Yu S; Chen P; Feng J
    Front Oncol; 2021; 11():699323. PubMed ID: 34336688
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives.
    Dormann C
    Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I-III HER2-Positive Breast Cancer: A Phase II Clinical Trial.
    Xuhong J; Qi X; Tang P; Fan L; Chen L; Zhang F; Tan X; Yan W; Zhong L; He C; Liang Y; Ren L; Wang M; Zhang Y; Jiang J
    Oncologist; 2020 Dec; 25(12):e1909-e1920. PubMed ID: 33000490
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer.
    Li X; Yang C; Wan H; Zhang G; Feng J; Zhang L; Chen X; Zhong D; Lou L; Tao W; Zhang L
    Eur J Pharm Sci; 2017 Dec; 110():51-61. PubMed ID: 28115222
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HDACs/mTOR inhibitor synergizes with pyrotinib in HER2-positive pancreatic cancer through degradation of mutant P53.
    Mao T; Zhang X; Xu H; Zhang X; Ge W; Li S; Ma J; Yue M; Xue S; Cui J; Wang L
    Cancer Cell Int; 2022 Dec; 22(1):380. PubMed ID: 36457011
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Sustained Clinical Benefit of Pyrotinib Combined with Capecitabine Rescue Therapy After Trastuzumab Resistance in HER2-Positive Advanced Gastric Cancer: A Case Report.
    Li X; Gu X; Xu J; Chen L; Li H; Meng D; Bai H; Yang J; Qian J
    Onco Targets Ther; 2021; 14():3983-3989. PubMed ID: 34234467
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pyrotinib in
    Zhou C; Li X; Wang Q; Gao G; Zhang Y; Chen J; Shu Y; Hu Y; Fan Y; Fang J; Chen G; Zhao J; He J; Wu F; Zou J; Zhu X; Lin X
    J Clin Oncol; 2020 Aug; 38(24):2753-2761. PubMed ID: 32614698
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Radiosensitization of HER2-positive esophageal cancer cells by pyrotinib.
    Lian X; Zhu C; Lin H; Gao Z; Li G; Zhang N; Cao B; Kang Y
    Biosci Rep; 2020 Feb; 40(2):. PubMed ID: 32022229
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Durable effect of pyrotinib plus capecitabine in HER-2+ breast cancer patient undergoing peritoneal dialysis: A case report and literature review.
    Jin X; Yan M; Li F
    Front Oncol; 2022; 12():1059670. PubMed ID: 36568221
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2-targeted therapies.
    Zhang C; Chen Z; Chong X; Chen Y; Wang Z; Yu R; Sun T; Chen X; Shao Y; Zhang X; Gao J; Shen L
    Clin Transl Med; 2020 Dec; 10(8):e254. PubMed ID: 33377634
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells.
    Huang T; Luo X; Wu B; Peng P; Dai Y; Hu G; Qiu H; Yuan X
    Oncol Rep; 2020 Dec; 44(6):2634-2644. PubMed ID: 33125154
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pyrotinib combined with CDK4/6 inhibitor in HER2-positive metastatic gastric cancer: A promising strategy from AVATAR mouse to patients.
    Chen Z; Xu Y; Gong J; Kou F; Zhang M; Tian T; Zhang X; Zhang C; Li J; Li Z; Lai Y; Zou J; Zhu X; Gao J; Shen L
    Clin Transl Med; 2020 Aug; 10(4):e148. PubMed ID: 32898333
    [TBL] [Abstract][Full Text] [Related]  

  • 76.
    Jia Z; Xing J; Li J; Wang W; Wang Y; Song Y; Yang X; Xue J; Ye J; Li B; Han-Zhang H; Zhao J; Zhang X; Peng F; Chen F; Chen X; Lu Y; Ying S; Wu D; Zhang X; Ma C; Lai L; Ma S; Liang D; Liu P; Li X; Liang N; Li S
    Transl Lung Cancer Res; 2021 Mar; 10(3):1383-1396. PubMed ID: 33889517
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Studies on the Safety and Efficacy of Pyrotinib in the Treatment of HER2- Positive Advanced Solid Tumors Excluding Breast Cancer.
    Yin Y; Yang H; Liu Z; Tan J; Zhu C; Chen M; Zhou R; Wang L; Qian J
    Cancer Manag Res; 2020; 12():13479-13487. PubMed ID: 33408520
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
    Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
    Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of pyrotinib or lapatinib with chemotherapy for patients with HER2 positive breast cancer after first-line treatment failure: a retrospective study.
    Yang H; Wang W
    Am J Transl Res; 2021; 13(9):10863-10870. PubMed ID: 34650767
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pyrotinib Sensitizes 5-Fluorouracil-Resistant HER2
    Yi J; Chen S; Yi P; Luo J; Fang M; Du Y; Zou L; Fan P
    Oncol Res; 2020 Dec; 28(5):519-531. PubMed ID: 32727638
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.